|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...4647484950515253545556...39323933» |
- Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche
Preliminary Safety and Efficacy Data of Combination Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Adriamycin, Prednisone (Pola-R-CHP) in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) in the Standard-of-Care Setting: A Single-Center Experience (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_755;
Longer follow-up is needed for survival outcomes analysis. The safety profile was similar to POLARIX trial.
- Rituxan (rituximab) / Roche
Management of Primary Mediastinal B-Cell Lymphoma in Morocco: A Monocentric Experience (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_754;
First-line treatments included: R-CHOP (n=41), R-ACVBP (n=2), R-DAEPOCH (n=2)... Our study confirms the efficacy of current PMBCL treatments despite the high mortality rate in our series, underscoring the need for therapeutic approaches that optimize remission while reducing long-term toxicity.
- Polivy (polatuzumab vedotin-piiq) / Roche
Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_753;
Our study confirms the efficacy of current PMBCL treatments despite the high mortality rate in our series, underscoring the need for therapeutic approaches that optimize remission while reducing long-term toxicity. Polatuzumab, an antibody
- Polivy (polatuzumab vedotin-piiq) / Roche, Rituxan (rituximab) / Roche, Epkinly (epcoritamab-bysp) / Genmab, AbbVie
First Data From Subcutaneous Epcoritamab + Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-RCHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5 (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_752;
P2
Epcoritamab+pola-R-CHP in newly diagnosed DLBCL showed high ORR and CR rates across all subgroups with a manageable safety profile. Data compare favorably with pola-R-CHP and other treatment regimens and support further investigation.
- Ordspono (odronextamab) / Regeneron, Yescarta (axicabtagene ciloleucel) / Gilead
Matching-Adjusted Indirect Comparison of Axicabtagene Ciloleucel vs Odronextamab for the Treatment of Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) After 2 Prior Lines of Systemic Treatment (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_751;
MAIC results suggest that one-time axi-cel treatment is associated with superior efficacy, including OS and PFS, relative to odronextamab, which is used in a treat-to-progression fashion. Although odronextamab patients appear to be at lower risk of grade 3+ CRS, these differences may be reduced using current safety protocols.
- Monjuvi (tafasitamab-cxix) / Incyte
Real-World Sequential Use of CD19-Directed Therapies for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab Preceding Chimeric Antigen Receptor T-Cell (CAR-T) Therapy (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_750;
Tafasitamab, a CD19-targeting immunotherapy, combined with lenalidomide, is approved for R/R DLBCL treatment in adults ineligible for autologous stem cell transplantation. This small real-world analysis demonstrated disease response to CD19-directed CAR-T therapy and detectable CD19 expression following tafasitamab treatment.
- Rituxan (rituximab) / Roche
Cell-Free Circulating DNA as a Prognostic Factor for Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Hepatitis C Virus (HCV) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_749;
Treatment of HCV to decrease the incidence of DLBCL is crucial, and assessing viral load during treatment of DLBCL is important. More work and larger studies are needed to confirm our findings.
- Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T-Cell Therapy in the US (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_748;
This is the first study to examine Lonca at 3L following CAR-T at 2L and suggests that Lonca can be a reasonable and effective treatment option for patients who are resistant/progressed after CAR-T. Data collection is still ongoing, and the final results will be presented at the meeting.
- Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Real-world Treatment Patterns and Outcomes of Patients with Large B-cell Lymphoma (LBCL) Who Received Loncastuximab Tesirine Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_747;
Data collection is still ongoing, and the final results will be presented at the meeting. The median LOTs prior to CAR-T (axicabtagene ciloleucel) was 4 (range: 2
- Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche, Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_746;
P1
Increased doses of Lonca in combinations were predicted to have limited additional therapeutic benefit; however, additional cycles of combination treatment were predicted to increase TGI. This model suggests that Lonca doses could be reduced to improve tolerability for longer periods of time, up to the point of maximal benefit, although clinical testing is needed to explore these results.
- Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma, Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_745;
While increased doses of Lonca had limited additional therapeutic benefit, combination treatment beyond C3 was predicted to increase depth of tumor regression. Response from Lonca and Epco codosing was predicted to be less affected by suppressed T-cell counts at baseline compared with Epco alone, which may enhance responsiveness when T-cell level is moderate.
- Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma
Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_744;
P1
Status: The study opened in December 2021. As of December 2023, 23 patients were enrolled, with 12 patients treated in arm C, 6 in arm E, and 4 in arm F.
- Zynlonta (loncastuximab tesirine-lpyl) / Overland ADCT BioPharma, Rituxan (rituximab) / Roche
LOTIS-5, an Ongoing, Phase 3, Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_743;
P3
Status: The randomized part of LOTIS-5 began in January 2022; the estimated primary completion date is September 2025. Enrollment continues; 254 patients are enrolled across North America, South America, Europe, and Asia.
- Columvi (glofitamab-gxbm) / Roche
Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_742;
P1/2
Enrollment continues; 254 patients are enrolled across North America, South America, Europe, and Asia. Design: Patients with LBCL and ?2 prior therapies received obinutuzumab pretreatment (1000mg) on Day (D)1 of Cycle (C)1, then intravenous glofitamab step-up doses during C1 (D8: 2.5mg; D15: 10mg) and target dose (30mg) on D1 of C2
- Rituxan (rituximab) / Roche
Real-World Efficacy and Toxicity of the LMBA02 Protocol for Burkitt Lymphoma in Morocco (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_740;
Design: Patients with LBCL and ?2 prior therapies received obinutuzumab pretreatment (1000mg) on Day (D)1 of Cycle (C)1, then intravenous glofitamab step-up doses during C1 (D8: 2.5mg; D15: 10mg) and target dose (30mg) on D1 of C2 Key findings from this analysis include comparable survival rates in adults with BL compared to previous real-life studies, a significant and high TRM rate, and a survival benefit associated with rituximab treatment.
- Rituxan (rituximab) / Roche
Diagnosis and Treatment of Primary Hepatic Lymphoma: Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_739;
It is difficult to make specific treatment recommendations for primary liver lymphoma. The course of treatment is based on the underlying pathological processes, the stage of the disease, and other confirmed prognostic factors.
- Kymriah (tisagenlecleucel-T) / Novartis
Durable Efficacy and Manageable Safety in Patients Aged ?75 Years With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Treated With Tisagenlecleucel in the Real-World Setting (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_738;
Tisagenlecleucel demonstrated similar efficacy and rates of CRS and ICANS in both age subgroups. Real-world evidence for patients aged ?75 years is invaluable for guiding treatment decisions.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Epcoritamab + GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2 (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_734;
P1/2
Context: Outcomes are suboptimal in R/R DLBCL treated with gemcitabine + oxaliplatin (GemOx) and rituximab: complete response (CR) rate, 33%; median progression-free survival (PFS), 5 months; median overall survival (OS), 10 months. Epcoritamab + GemOx continues to yield deep, durable responses and high PFS/OS rates for complete responders in high-risk, challenging-to-treat R/R DLBCL, supporting epcoritamab combination therapy.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Epcoritamab + R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_733;
P1/2
Epcoritamab + GemOx continues to yield deep, durable responses and high PFS/OS rates for complete responders in high-risk, challenging-to-treat R/R DLBCL, supporting epcoritamab combination therapy. Adults with R/R CD20+ DLBCL eligible for HDT-ASCT received rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin (R-DHAX/C) and subcutaneous epcoritamab (2 step-up doses, then 24- or 48-mg full doses) in 21-d cycles (Cs): QW, C1
- Rituxan (rituximab) / Roche
Neurolymphomatosis: An Unusual Manifestation of Relapsed/Refractory Lymphoma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_730;
Secondary neurolymphomatosis is an extremely rare condition, but a high degree of suspicion should be adapted for early recognition. Although there is no standard treatment, high dose methotrexate, rituximab and cytarabine has proven to give complete response in this case.
- Rituxan (rituximab) / Roche
Can Lymphoma Mimic Crohn's Disease? (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_729;
The patient received 6 cycles of R-CHOP chemotherapy for widespread nodal and extra nodal involvement of lymphoma...Besides histopathological evaluation, diagnoses should be reconsidered in cases of clinical suspicion. Differential diagnosis is crucial in diseases that can lead to similar symptoms.
- Rituxan (rituximab) / Roche
Case Report of Refractory Large B-Cell Lymphoma With IRF4 Rearrangement (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_728;
R-CHOP chemotherapy protocol was initiated...JAK2 fusion abnormalities are associated with treatment resistance in myeloid and lymphoblastic leukemias, but there are no data on their contribution to the clinical course in IRF4+LBCL. In our case with primary refractory course, it was considered that the additional JAK fusion abnormality may have had a negative effect on the clinical course.
- Rituxan (rituximab) / Roche
R-CHOP versus R-DAEPOCH for patients with newly diagnosed Double Expressor Lymphoma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_727;
This retrospective analysis does not support the use of R-DAEPOCH over R-CHOP for DEL, as CR rates and PFS are comparable in both treatment protocols. Prospective studies are required to confirm these findings.
- Rituxan (rituximab) / Roche
A Twist of Fate: A Case of Sequential Lymphoma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_726;
The rarity of such cases limits the availability of established treatment guidelines, necessitating a tailored approach based on patient-specific factors and prior treatment history. Further research is needed to better understand the optimal management of sequential lymphomas and improve outcomes for affected patients.
- Rituxan (rituximab) / Roche
Incidence and Type of Second Primary Malignancies After NHL-DLBCL (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_725;
Further research is needed to better understand the optimal management of sequential lymphomas and improve outcomes for affected patients. 82.1% were treated with anthracycline-based protocol
- Monjuvi (tafasitamab-cxix) / Incyte
Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_724;
Findings indicate that the response rates to tafasitamab were favorable among patients with primary refractory and nonprimary refractory DLBCL. Longer follow-up is required to evaluate long-term outcomes with tafasitamab treatment among patients with primary refractory DLBCL.
- Monjuvi (tafasitamab-cxix) / Incyte
Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (>70 Years and ?70 Years) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_723;
Real-world ORRs support the clinical benefit of tafasitamab among older (>70 years) and younger (?70 years) patients with R/R DLBCL. Longer follow-up is warranted to better assess long-term outcomes with tafasitamab by age.
- Breyanzi (lisocabtagene maraleucel) / BMS
Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_722;
P2
Liso-cel showed similar efficacy and safety (low rates of severe CRS/NEs/infections) in both subgroups, suggesting BT may slow disease progression (despite higher baseline disease burden), potentially improving outcomes in this high-risk population. Safety in the outpatient setting was consistent with the overall population and with liso-cel in OUTREACH (NCT03744676; LBCL outpatient setting), with no new safety signals.
- Rituxan (rituximab) / Roche, Calquence (acalabrutinib) / AstraZeneca
ACRUE: A Phase 2, Open-Label Study of Acalabrutinib in Combination With Rituximab in Elderly and/or Frail Patients With Treatment-Naive Diffuse Large B-Cell Lymphoma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_721;
P2
Safety in the outpatient setting was consistent with the overall population and with liso-cel in OUTREACH (NCT03744676; LBCL outpatient setting), with no new safety signals. This study will assess whether AR is tolerable and effective in elderly and/or frail patients with TN DLBCL who cannot tolerate CIT.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_720;
P1/2
No new safety signals were reported. Simple measures of prophylactic dexamethasone and adequate hydration in C1 decreased rates and severity of CRS.
- Polivy (polatuzumab vedotin-piiq) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Mosunetuzumab wWth Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_719;
P1/2
Simple measures of prophylactic dexamethasone and adequate hydration in C1 decreased rates and severity of CRS. Mosun-pola demonstrated durable benefits in ORR and CR rates irrespective of a poor response to 1L treatment.
- Rituxan (rituximab) / Roche
Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_718;
P3
Mosun-pola demonstrated durable benefits in ORR and CR rates irrespective of a poor response to 1L treatment. These findings suggest a benefit of Pola-R-CHP across COO subtypes; molecular profiling tools beyond COO are necessary to apply precision medicine for DLBCL and sufficiently address the heterogeneity of the disease.
- Successful Treatment of a Gray Zone Lymphoma With Immunotherapy: A Case Report (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_715;
Specifically, immune checkpoint inhibitors like nivolumab and pembrolizumab are being used to treat relapsed/refractory lymphomas... Multidisciplinary discussion suggested treatment with 6 cycles of R-CHOP and 2 cycles of R-methotrexate...After that, she received 2 cycles of brentuximab vedotin
- Rituxan (rituximab) / Roche
A Rare Case of Large B-cell Lymphoma Presenting as a Large Pericardial Effusion With Tamponade Physiology (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_711;
Multidisciplinary discussion suggested treatment with 6 cycles of R-CHOP and 2 cycles of R-methotrexate...After that, she received 2 cycles of brentuximab vedotin He started inpatient chemotherapy with DA-EPOCH-R (dose-adjusted
- Rituxan (rituximab) / Roche
Tumor CD20 Loss and Poor Outcome in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_710;
CD19 expression did not impact outcomes. However, a larger cohort and longer follow-up are needed to understand its significance.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Outcomes With Epcoritamab in Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_709;
Epcoritamab demonstrated promising results, indicating potential for improved patient outcomes. Further exploration of epcoritamab in earlier lines of therapy or in combination with other agents will expand its patient population and avenues of treatment.
- Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Epcoritamab as Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_708;
Initial outcomes were poor in patients who had poor performance status or who did not achieve any response to CAR T-cell therapy. Longer follow-up is needed to determine if the efficacy of SOC epcor is comparable to that reported in clinical trials.
- Rituxan (rituximab) / Roche
Utility of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma Patients (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_706;
Contrary to expectations, our study findings suggest that the addition of HD-MTX to IT-MTX for CNS prophylaxis in high-risk DLBCL patients may not provide additional protective benefits and could potentially increase the risk of CNS relapse. Further research is warranted to elucidate optimal CNS prophylactic regimens in this patient population.
- Rituxan (rituximab) / Roche
A Proposed Prognostic Score Including Circulating Free DNA (ctDNA) Concentration in Diffuse Large B-Cell Lymphoma (DLBCL): Single Centre Study (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_705;
We proposed a prognostic score that showed a significant correlation to OS. The advantage of our score is that it is applicable and cost-effective to be used when the mutational analysis techniques are not available.
- Gazyva (obinutuzumab) / Roche, Biogen
Is Obi-Benda-Len a New Chance for Relapsed or Refractory B-Cell Lymphoma Patients? (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_703;
The low PFS rates in our patient group are probably due to the fact that we preferred this combination therapy at later stages. Choosing it at earlier stages seems to increase the success rate.
- Rituxan (rituximab) / Roche
Azacytidine plus rituximab (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_701;
Choosing it at earlier stages seems to increase the success rate. Our study shows that AZA+ R-GemOx is a highly feasible, safe, and effective therapy for R/R DLBCL.
- Rituxan (rituximab) / Roche
Experience in Diagnosis and Management of Lymphoma in Conception (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_695;
Patients with HL received ABVD with omission of bleomycin; those who relapsed received BEACOPP with reduced dose (25%) of bleomycin...Before chemotherapy, 3 patients received (R-CHOP) after their 20th week of gestation fractionated over 2 days, with reduced adriamycin dose (25%)... The major challenge was to stage and optimize the treatment approach offered to the mother, while limiting the impact on the fetus.
- Opdivo (nivolumab) / BMS, Gazyva (obinutuzumab) / Roche, Biogen, Imbruvica (ibrutinib) / AbbVie, J&J
Rare Cases of Hodgkin Lymphoma Transformation in Chronic Lymphocytic Leukemia: Challenges in Diagnosis and Management (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_692;
Understanding the underlying mechanisms, such as shared genetic aberrations and immune dysregulation, is crucial for developing targeted therapies. Management requires a multidisciplinary approach, considering disease burden, prognostic markers, and patient factors.
- Rituxan (rituximab) / Roche
Lymphoma Diagnosis Delay: Biopsy Strategy Insights (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_691;
However, persistent B symptoms, including fevers and night sweats, resulted in treatment with single-agent rituximab despite stable disease on interval imaging, which did not result in symptomatic improvement... CNB has proven to be inferior to surgical excision in providing a definite diagnosis in lymphoma workup; therefore, the latter should be considered early in diagnosing and timely managing the disease.
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
From Hodgkin Lymphoma to Mycosis Fungiodes: A Quick Cascade (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_690;
He underwent treatment with adriamycin, bleomycin sulfate, vinblastine sulfate, and dacarbazine...Brentuximab had previously been discussed; however, advanced disease and the development of multiorgan failure precluded further treatment... Maintaining a broad differential for cutaneous involvement of hematological malignancies is essential; tissue biopsy is vital for prompt and targeted treatment.
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Concomitant Methotrexate Withdrawal and Brentuximab Vedotin Therapy for Treatment of Methotrexate Associated Hodgkin Lymphoma (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_687;
Although the patient unfortunately succumbed, we anticipate that concomitant withdrawal of MTX and use of BV will be more effective than withdrawal of MTX alone in comorbid patients with MTX-associated HL. We aim to demonstrate that these treatment modalities can be combined, and we propose further investigation into the combined withdrawal of MTX and use of BV in this patient population.
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Simultaneous Hodgkin Lymphoma Diagnosis in 2 Sisters: Is This a Coincidence? (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_684;
Familial predisposition to HL is not well evaluated. Our report suggests that HL in first-degree relatives increases lymphoma risks in other siblings, not only in identical twins.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Roche
Systemic AA Amyloidosis as a Complication of Idiopathic Multicentric Castleman's Disease (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_650;
Experience with systemic AA amyloidosis complicating iMCD is scarce. In our case, anti
- Rituxan (rituximab) / Roche
Marginal Zone Lymphoma in the Landscape of Autoimmune Complexity: A Case Report With Sj (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_644;
This case illuminates the complex interplay between autoimmune diseases and lymphoproliferative disorders, stressing the importance of a team-based approach in diagnosis and treatment. It showcases the necessity for meticulous diagnostic work to identify and treat potential malignancies within autoimmune diseases, highlighting the crucial role of a multidisciplinary team in managing such intricate medical conditions.
- Investigating the Therapeutic Potential of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes: A Comprehensive Review and Analysis (LEVEL 3, HALL B3) - Aug 30, 2024 - Abstract #SOHO2024SOHO_580;
However, larger studies with longer follow-up are needed to fully understand the effectiveness of these regimens and identify biomarkers for response or resistance. The integration of ICIs into MDS treatment strategies has the potential to improve patient outcomes and advance personalized therapeutic approaches.